Zai discontinuing atopic dermatitis therapy

Zai Lab Ltd. (NASDAQ:ZLAB) said it will discontinue development of fugan (ZL-3101) to treat atopic dermatitis after it

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE